A potent specific pure antiestrogen with clinical potential.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Cancer Research

• Publication date

  1991-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 1855205
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

  1991cited by this paper
• Estrogen Deprivation in Breast Cancer

  1990cited by this paper
• Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen.

  1990cited by this paper
• Endocrine pharmacology of antiestrogens as antitumor agents.

  1990cited by this paper
• Therapeutic potential of pure antioestrogens in the treatment of breast cancer.

  1990cited by this paper
• Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.

  1990cited by this paper
• Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.

  1990cited by this paper
• Tamoxifen for breast cancer: Associated endometrial cancer

  1990cited by this paper
• Antagonism of estrogen- and antiestrogen-induced uterine complement component C3 expression by ICI 164,384.

  1990cited by this paper
• Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.

  1990influential reference
• A comparative study of the interaction of oestradiol and the steroidal pure antioestrogen, ICI 164,384, with the molybdate-stabilized oestrogen receptor.

  1990cited by this paper
• Tamoxifen as an Agonist for Metastatic Breast Cancer

  1990cited by this paper
• Novel Pure Antiestrogens. Mode of Action and Therapeutic Prospects

  1990cited by this paper
• Tamoxifen for breast cancer: Associated endometrial cancer

  1990cited by this paper
• Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells.

  1989cited by this paper
• Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle.

  1989cited by this paper
• Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.

  1989cited by this paper
• Growth kinetics of four human breast carcinomas grown in nude mice

  1989cited by this paper
• Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells.

  1989cited by this paper
• Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice.

  1989cited by this paper
• Biology and mode of action of pure antioestrogens.

  1989cited by this paper
• ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.

  1989cited by this paper
• Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence.

  1989cited by this paper
• Novel steroidal pure antiestrogens.

  1989cited by this paper
• Biology and mode of action of pure antioestrogens.

  1988cited by this paper
• Novel antioestrogens without partial agonist activity.

  1988cited by this paper
• Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.

  1988cited by this paper
• Actions of oestrogens and antioestrogens on rat mammary gland development: relevance to breast cancer prevention.

  1988cited by this paper
• Antioestrogens in the management of hormone-dependent cancer.

  1988cited by this paper
• Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells.

  1988cited by this paper
• Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens.

  1987cited by this paper
• Steroidal pure antioestrogens.

  1987cited by this paper
• Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells.

  1987cited by this paper
• Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.

  1985cited by this paper
• The pharmacology and clinical uses of tamoxifen.

  1984cited by this paper
• Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare.

  1984cited by this paper
• Comparison of the biological effects of tamoxifen and a new antioestrogen (LY 117018) on the immature rat uterus.

  1983cited by this paper
• Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites.

  1980cited by this paper
• Hormone dependency of a serially transplantable human breast cancer (Br-10) in nude mice.

  1977cited by this paper
• Radioimmunoassay for bovine and ovine luteinizing hormone.

  1969cited by this paper

• The median preoptic nucleus is a key site for estradiol regulation of sleep-wake behaviors in females rats.

  2026cites this paper
• The Median Preoptic Nucleus is a Key Site for Estradiol Regulation of Sleep-Wake Behaviors in Females Rats

  2025cites this paper
• Genistein and 17β-Estradiol Inhibit Extracellular Matrix Production and Chondroitin Sulfate Synthesis in ATDC5 Cells.

  2025cites this paper
• Novel Estrogen Receptor – Targeted Therapies in Hormone-Receptor Positive Breast Cancer

  2025cites this paper
• Hydrophobic tagging: A promising paradigm for targeted protein degradation

  2025cites this paper
• Multi-behavioral fingerprints can identify potential modes of action for neuroactive environmental chemicals.

  2025cites this paper
• Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant

  2025cites this paper
• Drug discovery for chemotherapeutic resistance based on pathway-responsive gene sets and its application in breast cancer

  2025cites this paper
• From serendipity to strategy: molecular glue degraders in cancer therapeutics

  2025cites this paper
• Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action

  2025cites this paper
• Integrating deep learning and molecular dynamics simulations for FXR antagonist discovery

  2025cites this paper
• A Revisit on FDA Approved Anticancer Drugs (1949 – 2024)

  2024cites this paper
• Targeting systemic and gut microbial metabolism in ER+ breast cancer.

  2024cites this paper
• The Role of Small Molecules Containing Fluorine Atoms in Medicine and Imaging Applications

  2024influential citation
• Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer

  2024cites this paper
• NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target

  2024cites this paper
• Methylimidazolium ionic liquids - a new class of forever chemicals with endocrine disrupting potential.

  2024cites this paper
• Induced protein degradation for therapeutics: past, present, and future

  2024cites this paper
• Rat Models of Hormone Receptor-Positive Breast Cancer

  2024cites this paper
• Cocaine sensitization in male rats requires activation of estrogen receptors

  2024cites this paper
• Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function

  2023influential citation
• Therapeutic resistance to anti-oestrogen therapy in breast cancer

  2023cites this paper
• Small Change - Big Consequence: The Impact of C15-C16 Double Bond in a D‑ring of Estrone on Estrogen Receptor Activity.

  2023cites this paper
• Synthetic Ionizable Colloidal Drug Aggregates Enable Endosomal Disruption

  2023cites this paper
• A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models

  2023cites this paper
• Wnt Signaling Stimulates Cooperation between GREB1 and HNF4α to Promote Proliferation in Hepatocellular Carcinoma.

  2023cites this paper
• An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER+) Breast Cancer: Effects on Sensitive and Resistant Cell Lines

  2023cites this paper
• Combined Application of Honokiol and 2-Deoxyglucose against MCF7 Breast Cancer Cells Under Hypoxia

  2023cites this paper
• Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?

  2023cites this paper
• Estrogen contributes to sex differences in M2a macrophages during multi‐walled carbon nanotube‐induced respiratory inflammation

  2023cites this paper
• Tamoxifen evolution

  2023cites this paper
• Structural determinants of pure antiestrogenicity

  2023cites this paper
• Place of fulvestrant in the treatment of patients with metastatic luminal Her2-negative breast cancer

  2023cites this paper
• Tamoxifen's patenting problems in America, which created a “cancer treatment company”

  2022cites this paper
• Integrated genomic analysis to identify druggable targets for pancreatic cancer

  2022cites this paper
• Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

  2022influential citation
• Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

  2022influential citation
• An overview on Estrogen receptors signaling and its ligands in breast cancer.

  2022cites this paper
• Computational Approaches to Identify a Novel Binding Site of BHPI on Estrogen Receptor Alpha.

  2022cites this paper
• Design, Semisynthesis, and Estrogenic Activity of Lignan Derivatives from Natural Dibenzylbutyrolactones

  2022cites this paper
• Impact of preovulatory estradiol concentrations on subsequent luteal function in beef cattle

  2022influential citation
• Do axis gut-breast microbiota orchestrate cancer progression?

  2022cites this paper
• In vitro toxicity studies of novel solar water disinfection reactors using the E-screen bioassay and the Ames test

  2021cites this paper
• Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer

  2021cites this paper
• Effects of the Mixture of Erigeron floribundus (Asteraceae) and Tragia benthamii (Euphorbiaceae) on the Growth and Architecture of Estrogen-Sensitive Sexual Organs

  2021cites this paper
• A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy

  2021cites this paper
• Discovery of GNE-502 as an Orally Bioavailable and Potent Degrader for Estrogen Receptor Positive Breast Cancer.

  2021cites this paper
• Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

  2021cites this paper
• ERα-dependent estrogen-TNFα signaling crosstalk increases cisplatin tolerance and migration of lung adenocarcinoma cells.

  2021cites this paper
• Mechanisms of Endocrine Therapy Resistance in Breast Cancer.

  2021cites this paper
• Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.

  2021cites this paper
• Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches

  2021cites this paper
• Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

  2021cites this paper
• Current State of Breast Cancer Diagnosis, Treatment, and Theranostics

  2021influential citation
• The E-Morph Assay: Identification and characterization of environmental chemicals with estrogenic activity based on quantitative changes in cell-cell contact organization of breast cancer cells.

  2021cites this paper
• A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy

  2021cites this paper
• Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

  2021cites this paper
• Breast Cancer Treatments: Updates and New Challenges

  2021cites this paper
• Estrogenski ili anti-estrogenski učinci ekstrakata tradicionalno korištenih tropskih biljaka na ljudske

  2021cites this paper
• Management of Early Stage Breast Cancer: Basics and Controversies

  2021cites this paper
• Assessment of the in vitro developmental toxicity of diethylstilbestrol and estradiol in the zebrafish embryotoxicity test.

  2021cites this paper
• Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

  2021cites this paper
• BPB Reports

  2020cites this paper
• Apoptosis in Response to Anti-estrogens in MCF-7 Cells [MJM 1995 1:111-118]

  2020cites this paper
• Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives

  2020cites this paper
• A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.

  2020cites this paper
• Metalloestrogenic effects of cadmium are absent in long-term estrogen-deprived MCF-7 cells: evidence for the involvement of constitutively activated estrogen receptor α and very low expression of G protein-coupled estrogen receptor 1.

  2020cites this paper
• Clarkson, Richard 2018. Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP

  2020cites this paper
• A homogeneous bioluminescent immunoassay to probe cellular signaling pathway regulation

  2020cites this paper
• A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HR-Positive, HER2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.

  2020cites this paper
• Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival

  2020cites this paper
• Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

  2020cites this paper
• 27‐Hydroxycholesterol regulates human SLC22A12 gene expression through estrogen receptor action

  2020cites this paper
• Molecular Mechanisms of Early Breast Cancer

  2020cites this paper
• Estrogens Determine Adherens Junction Organization and E-Cadherin Clustering in Breast Cancer Cells via Amphiregulin

  2020cites this paper
• Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China

  2020cites this paper
• 50th ANNIVERSARY OF THE FIRST CLINICAL TRIAL WITH ICI 46,474 (TAMOXIFEN): THEN WHAT HAPPENED?

  2020cites this paper
• Breast cancer animal models and applications

  2020cites this paper
• Transcription Factors in Cancer Development and Therapy

  2020cites this paper
• Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition

  2020influential citation
• Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.

  2020cites this paper
• Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives

  2020cites this paper
• Computer-Aided Ligand Discovery for Estrogen Receptor Alpha

  2020cites this paper
• Different effects of total flavonoids from Arachniodes exilis on human umbilical cord mesenchymal stem cells in vitro

  2020cites this paper
• Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

  2020cites this paper
• Ribociclib plus fulvestrant in the treatment of breast cancer

  2020cites this paper
• Molecular mechanisms underlying AMH elevation in hyperoestrogenic states in males

  2020cites this paper
• Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.

  2020cites this paper
• Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.

  2020cites this paper
• The Predictive Value of Early Changes in F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

  2020cites this paper
• The Predictive Value of Early Changes in 18 F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

  2020cites this paper
• Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives

  2020influential citation
• Characterising the role of TET2 in oestrogen receptor positive breast cancer

  2020cites this paper
• Estrogen Receptors in Nonfunctioning Pituitary Neuroendocrine Tumors: Review on Expression and Gonadotroph Functions

  2020cites this paper
• Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review

  2019cites this paper
• Controlling the Stability of Colloidal Drug Aggregates for Chemotherapeutic Delivery

  2019cites this paper
• Epigenetic regulation by estrogen receptor in breast cancer cells

  2019cites this paper
• Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come.

  2019cites this paper
• Estrogen stimulates SREBP2 expression in hepatic cell lines via an estrogen response element in the SREBP2 promoter

  2019cites this paper
• Human URAT1/SLC22A12 gene promoter is regulated by 27-hydroxycholesterol through estrogen response elements

  2019cites this paper